Thoracic Vascular Stent Grafts Market

Thoracic Vascular Stent Grafts Market Outlook

The thoracic vascular stent grafts market is anticipated to flourish at an average CAGR of 3.4% between 2023 and 2033. The market is expected to hold a market share of USD 278.9 million by 2033 while the market is likely to reach a value of USD 199.3 million in 2023.

Thoracic vascular stent grafts, also known as thoracic, vascular aneurysm repair. It is a surgical procedure. The demand for the same spike is carried out as an alternative to conventional surgery for the repair of the aortic aneurysm.

Thoracic aneurysm is a bulge in the major artery from the heart which dilates the diameter of the aorta by greater than 150%. This may lead to rupturing or tearing and subsequent internal bleeding, and this is when these grafts come to the fore.

Thoracic vascular stent grafting is a new form of treatment in the vascular stent grafts industry showing promising results. The thoracic vascular stent grafts market growth is fostered by the FDA approval of the thoracic vascular stent grafts in 2005 for descending thoracic aortic aneurysm.

Attribute	Details
Thoracic Vascular Stent Grafts Market CAGR (2023 to 2033)	3.4%
Thoracic Vascular Stent Grafts Market Size (2023)	USD 199.3 million
Thoracic Vascular Stent Grafts Market Size (2033)	USD 278.9 million

There are many different types of stent grafts available in the market, which differ in their insertion procedure and access to the blood vessel. Further, increasing prevalence has been observed in the thoracic aortic aneurysm condition, thus representing a huge opportunity for the market players to launch innovative as well as cost-effective products.

An estimated 21,000 individuals got affected every year in the United States and a prevalence of 10.4 per 10,000 persons has been observed in the United Kingdom. This represents a huge demand for thoracic vascular stent grafts during the forecast period. Moreover, the strict regulatory conditions regarding stent grafts help in keeping the record of several implants in different regions.

Several players in the market are focusing on key emerging markets for huge growth potential and increased distribution channels in these regions. Moreover, the market growth is further facilitated by the fact that thoracic vascular stent grafts represent the only option for elderly patients who cannot withstand the traditional surgery procedure.

What are the Key Thoracic Vascular Stent Grafts Market Dynamics?

Government funding for the development of cost effective healthcare solutions and increase in improvement in diagnostic services are likely to propel the sales of thoracic vascular stent grafts.

Rise in geriatric population in tandem with increasing lifestyle related disorders is expected to boost the demand for these stent grafts. Moreover, the preference of minimal invasive procedures over the conventional surgery owing to less pain, less hospitals stay, less blood loss and low risk of death also supports the market growth.

Growing number of commercially available different types of thoracic vascular stent graft designs also expands the thoracic vascular stent grafts market size. However, poor access to diagnosis in low income countries, lack of trained personnel, and lack of evidence in long term results limits the market growth for the global market of thoracic vascular stent grafts.

Country-wise Insights

Countries	Revenue Share % (2022)
The United States	34.0%
Germany	5.7%
Japan	4.1%
North America	36.7%
Europe	28.3%

Countries	CAGR % (2023 to 2033)
China	4.1%
India	3.5%
The United Kingdom	2.6%
Australia	2.8%

Why is North America Expected to Lead the Thoracic Vascular Stent Grafts Market?

Government funding for the development of cost-effective healthcare solutions and increased improvement in diagnostic services are likely to propel the sales of thoracic vascular stent grafts. North America held a market share of 36.7% in 2022.

A rise in the geriatric population in tandem with increasing lifestyle-related disorders is expected to boost the demand for stent grafts. Further, the preference for minimally invasive procedures over conventional surgery owing to less pain, a few hospitals stays; less blood loss and low risk of death also support the market growth.

A growing number of commercially available different types of thoracic vascular stent graft designs also expand the thoracic vascular stent grafts market size. However, poor access to diagnosis in low-income countries, lack of trained personnel, and lack of evidence in long-term results limit the market growth for the global market of thoracic vascular stent grafts.

What are the Growth Prospects for Europe’s Thoracic Vascular Stent Grafts Market?

This is followed by the Western Europe region, with EU5 leading the market share as per the current sales trend for these devices, contributing to the region’s thoracic vascular stent grafts market share of 28.3% in 2022.

Technical breakthroughs have occurred on account of the significant increase in the number of conventional graft failures. Medtronic, for example, gained CE Mark for their Endurant II/IIs stent graft system for the treatment of abdominal aortic aneurysms, advancing the market in the region.

Category-wise Analysis

Category	By Product Type
Leading Segment	Metal Thoracic Vascular Stent Graft
Market Share% (2022)	62.1%

Category	By End Use type
Leading Segment	Hospitals
Market Share% (2022)	77.2%

Based on the product type, the metal segment leads the market as it held a market share of 62.1% in 2022. Based on the end use type, the hospitals segment runs forward by holding a market share of 77.2% in 2022.

How is the Start-Up Ecosystem in the Thoracic Vascular Stent Grafts Market?

Numerous thoracic vascular stent graft start-ups are coming up. One of the significant ones is Aortica, a Seattle-area biotech. It is developing a tailored approach to treating aortic aneurysms, specifically complicated abdominal aortic aneurysms, which are difficult to cure.

The start-up has secured just over USD 1 million of a USD 4 million round of insider funding to further develop the treatment Aortica. CEO and founder Thomas Douthitt told GeekWire that the company has pledged to finish the entire USD 4 million round.

Dr Benjamin Starnes, a prominent surgeon who oversees vascular surgery at the University of Washington Medical Center and Harborview Medical Center in Seattle, created Aortica in 2014. He is now heading clinical trials of Aortica's technology at Harborview.

Competitive Landscape

Relentless competition is experienced by top manufacturers owing to the emergence of start-up companies in this sector, as well as the increasing sales of 3D TVS packages.

Recent Developments:

• Terumo Corporation, for example, announced the acquisition of Aortic Corporation. The acquisition boosted the company's vascular grafts business segment's expansion and contributed to individualized aortic therapy.
• C. R. Bard, Inc. has been acquired by BD. It sought to strengthen the company's leadership in infection prevention and medication management through an enlarged solution portfolio across the care continuum, as well as to explore growth prospects outside of the United States market.

Key Players Profiled in the Market

• Medtronic
• Jotec GmbH
• Cook medical
• MicroPort Scientific Corporation
• Terumo Corporation
• Others

Key Segments Covered

By Product Type:

• Plastic Thoracic Vascular Stent Grafts
• Metal Thoracic Vascular Stent Grafts)

By End Use:

• Hospitals
• Ambulatory Surgical Centers

Key Regions Covered:

• North America
  • The United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • The United Kingdom
  • France
  • Spain
  • Russia
  • Rest of Europe
• Japan
• Asia Pacific Excluding Japan
  • China
  • India
  • Malaysia
  • Singapore
  • Australia
  • Rest of Asia Pacific Excluding Japan (APEJ)
• Middle East and Africa
  • GCC Countries
  • Israel
  • South Africa
  • The Middle East and Africa (MEA)

Frequently Asked Questions

How Big is the Thoracic Vascular Stent Grafts Market?

The market held a value of USD 194 million in 2022.

What is the Key Segment by Product Type?

Metal thoracic vascular stent grafts segment dominates the market.

What is the Go-to Market Strategy?

Focus on innovative and cost-effective products for thoracic vascular stent grafts.

Which are the Key Asian Countries in the Thoracic Vascular Stent Grafts Market?

China, India, Malaysia, Singapore, and Australia are key regions.

Which Industry is the Key Consumer of Thoracic Vascular Stent Grafts?

Healthcare and hospitals are the key consumers.